Su Christopher T, Veenstra Christine M, Patel Minal R
Institute for Healthcare Policy and Innovation, University of Michigan, Ann Arbor, MI 48109, USA.
Division of Hematology and Oncology, Department of Internal Medicine, University of Michigan, Ann Arbor, MI 48109, USA.
Cancers (Basel). 2022 Mar 22;14(7):1605. doi: 10.3390/cancers14071605.
Introduction: Important differences exist between the presentation, treatment, and survivorship of patients and survivors with blood cancers. Furthermore, existing research in financial toxicity has not fully addressed the relationship between medical care utilization and patient-reported outcomes of financial barriers and distress. We answered these questions by using a nationally representative survey. Methods: Respondents with blood cancers and solid tumors from the National Health Interview Survey were identified (2014−2020). We identified 23 survey questions as study outcomes and grouped them into three domains of medical care utilization, financial barriers to care, and financial distress. Associations between the three domains and associations of study outcomes between cancer types were examined using weighted univariate analyses and multivariable linear and logistic regressions. Results: The final study group consisted of 6248 respondents with solid tumors and 398 with blood cancers (diagnosed ≤ 5 years). Across all respondents with cancer, higher medical care utilization is generally associated with increased financial barriers to care. Compared to respondents with solid tumors, respondents with blood cancers had a higher level of medical care utilization (β = 0.36, p = 0.02), a lower level of financial barriers to care (β = −0.19, p < 0.0001), and a higher level of financial distress in affording care (β = 0.64, p = 0.03). Conclusions: Patients and survivors with blood cancers and solid tumors demonstrate divergent patterns in care utilization, financial barriers, and financial distress. Future research and interventions on financial toxicity should be tailored for individual cancer groups, recognizing the differences in medical care utilization, which affect the experienced financial barriers.
血癌患者及幸存者在临床表现、治疗和生存方面存在重要差异。此外,现有关于经济毒性的研究尚未充分探讨医疗服务利用与患者报告的经济障碍和困扰结果之间的关系。我们通过一项具有全国代表性的调查回答了这些问题。方法:从国家健康访谈调查中识别出血癌和实体瘤患者(2014 - 2020年)。我们将23个调查问题确定为研究结果,并将它们分为医疗服务利用、医疗护理的经济障碍和经济困扰三个领域。使用加权单变量分析以及多变量线性和逻辑回归来检验这三个领域之间的关联以及癌症类型之间研究结果的关联。结果:最终研究组包括6248名实体瘤患者和398名血癌患者(诊断时间≤5年)。在所有癌症患者中,较高的医疗服务利用率通常与更高的医疗护理经济障碍相关。与实体瘤患者相比,血癌患者的医疗服务利用率更高(β = 0.36,p = 0.02),医疗护理的经济障碍水平更低(β = -0.19,p < 0.0001),在支付医疗费用方面的经济困扰水平更高(β = 0.64,p = 0.03)。结论:血癌和实体瘤患者及幸存者在医疗服务利用、经济障碍和经济困扰方面表现出不同模式。未来关于经济毒性的研究和干预措施应针对个体癌症群体进行定制,认识到医疗服务利用的差异会影响所经历的经济障碍。